Sign in
WithdrawnPhase 1

Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1
Started
31 Jan 2024
Expected to end
30 Jun 2029
Type of study
Interventional
Treatments tested
  • UKidney
Record updated
1 February 2024
Why it stopped
Approval to move forward with this clinical trial has not been granted by governing bodies.

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Ages 18-75 years
  • Body mass index (BMI) 18-40 kg/m2
  • Waitlisted for kidney allotransplantation at UAB
  • Dialysis dependent
  • Proficient in the English language
  • Presence of risk factors for; high wait list mortality, AND/OR; anticipated or actual prolonged wait time on the wait list, AND/OR; inability to access a suitable organ offer; Note: Examples of risk factors include high cPRA, frequent incompatible crossmatches leading to prolonged wait times, listing at an advanced age, and impending loss of dialysis access, recurrent disease in previous transplants
  • Crossmatch compatible with porcine donor
  • SARS-CoV-2 vaccination in accordance with most recent CDC guidance
  • Willingness to obtain other standard-of-care vaccinations for kidney transplant recipients (MMR, HBV, Herpes Zoster, etc.) and for patients receiving eculizumab (Menactra® and Bexsero®)
  • Reside within a 60-minute radius of the UAB hospital (by ground transport)

Who cannot take part

  • Current use/abuse of illicit drugs and/or abuse of alcohol
  • Pre-emptive transplant
  • Presence of hypercoagulable disorder
  • History of medical non-compliance
  • Presence of untreated psychiatric disease
  • History of psychiatric hospitalization
  • Presence of severe comorbid disease, including but not limited to uncontrolled HTN or DM (hemoglobin A1C (HgA1C) >10%), advanced cardiovascular disease, absent surgical targets for implantation, etc
  • Age <18y or ≥ 76y
  • BMI ≤ 18 or ≥ 41 kg/m2
  • Current pregnancy
  • Inability to accept a blood transfusion
  • Intolerance of immunosuppression
  • Significant psychosocial vulnerability and/or poor social support
  • Inability to provide informed consent
  • Inability to comply with study protocols and procedures

Where in United States

  • University of Alabama BirminghamBirmingham, United States

About the trial

What the trial wants to find out

The mismatch between organ supply and demand results in the deaths of thousands of Americans each year. Our research group aims to solve this unmitigated health care crisis by translating advances in xenotransplantation to humans and expanding organ supply in a sustainable fashion using genetically modified pigs as a source of organs. We propose here a phase I clinical trial of porcine kidney xenotransplantation into 20 people with end-stage kidney disease. Source donor animals are pigs with 10 gene edits (10-GE) which attenuate immunologic harm to the kidney xenograft. 10-GE pigs are housed in a designated pathogen-free facility within 30 minutes of the transplantation center. Xenotransplantation procedures follow conventional practices currently employed in allotransplantation and comply with multiple regulatory standards to ensure ethical treatment of research subjects and source animals. Recruitment and xenotransplantation will occur over 5 years with study follow-up extending 1 year after xenotransplantation. Primary outcome variables surround patient safety, such as patient survival and the rate of zoonotic disease transmission. Secondary outcome variables include commonly used metrics of graft survival and function.

The group in the trial

  • Porcine Kidney (UKidney) transplantTreatment being tested

    In this phase I single arm study patients with acute renal failure will be transplanted with a porcine xenograft versus a human allograft-after transplantation the best practice standard of care will be followed for monitoring and immunosuppression with the exception of additional monitoring for potential porcine transmitted infections

    Treatment: UKidney

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
1 February 2024